Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
All participants underwent comprehensive geriatric assessment (CGA) and cardiopulmonary exercise testing (CPET). A personalized management program was developed for each patient, including recommendations on physical exercise, nutrition, correction of geriatric syndromes, optimization of somatic status, and medication therapy adjustment. The program was delivered in a hospital setting over 3-5 days, with recommendations provided for continuation at the outpatient stage for 6 months. Upon completion of the 6-month program, CGA and CPET were repeated to evaluate the effectiveness of the programs.
All participants underwent comprehensive geriatric assessment (CGA) and cardiopulmonary exercise testing (CPET). After this the participants will undergo geriatric rehabilitation programs. The participation duration will not exceed 6.5 months including the screening period.
The study comprises three periods:
The inpatient phase will last 3-5 days and will include:
Final visit will be performed at the end of rehabilitation program. It will include:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Frailty | Experimental | Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA and CPET |
|
| Prefrailty | Experimental | Pre-Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA and CPET |
|
| Robust | Experimental | Non-frail Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA and CPET |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Geriatric rehabilitation program based on CGA and CPET | Other | Geriatric rehabilitation program based on CGA and CPET will be performed under physicians' tight control over 3-5 days, followed by outpatient continuation for 6 months. After 6 months, CGA and CPET will be repeated to evaluate program effectiveness. |
| Measure | Description | Time Frame |
|---|---|---|
| functional status dynamics | Instrumental and Basic Activity Daily Life scale score | 6 months |
| Change in aerobic exercise capacity | eak oxygen uptake (VO₂ peak) measured during cardiopulmonary exercise testing (CPET) | 6 months |
Not provided
Not provided
Inclusion Criteria:
1. Men and women aged 60 and older who wanted to participate in the study and signed a consent form.
Exclusion Criteria:
60 years old and older
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Olga N Tkacheva, Dr. | Pirogov Russian National Research Medical University, the Russian Research and Clinical Center for Gerontology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Russian Research and Clinical Center for Gerontology | Moscow | 129226 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
his is a prospective, non-randomized, parallel-group study. Participants are assigned to one of three final groups (Robust, Prefrailty, Frailty) based on a sequential algorithm using the questionnaire "Vozrast ne pomekha" (0-7 points) and the Short Physical Performance Battery (SPPB; 0-12 points):
Step 1 - Questionnaire "Vozrast ne pomekha" score:
< 3 points → further stratified by SPPB: SPPB 10-12 → Robust SPPB 8-9 → Prefrailty SPPB ≤7 → Frailty 3-4 points → further stratified by SPPB: SPPB ≥8 → Prefrailty SPPB ≤7 → Frailty
≥ 5 points → Frailty (regardless of SPPB score)
Not provided
Not provided
Not provided
Not provided
|
| ID | Term |
|---|---|
| D000073496 | Frailty |
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C039811 | Clostridium perfringens epsilon-toxin |
Not provided
Not provided
Not provided